GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced that ProFound Therapeutics and Quotient Therapeutics have entered into separate ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GlaxoSmithKline (GSK) has announced the purchase of 243,000 of its own ordinary shares ...

As GSK's vaccine ambitions grow with the launch of new respiratory syncytial virus (RSV) shot Arexvy, the company is once again investing to support its manufacturing operations. The British pharma is ...

A strong performer already, GSK stock is trading up 44% in 2025, yet its stock remains a good bargain. GSK trades for a ...

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership ...

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to ...

GSK struck a deal worth up to $1.7 billion with China-based Hansoh Pharma to pick up the rights to an antibody-drug conjugate (ADC), HS-20093, which is being investigated in cancer. The exclusive ...